Jessica A Slostad, Minetta C Liu, Jacob B Allred, Lori A Erickson, Kandelaria M Rumilla, Matthew S Block, Michael Keppen, David King, Svetomir N Markovic, Robert R McWilliams
Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it, 4 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 5 institutions in 1 country.
Jessica A SlostadDivision of Hematology-Oncology, Rush University Medical Center, Chicago, IL.
Minetta C LiuDivision of Medical Oncology, Mayo Clinic, Rochester, MN.
Jacob B AllredAlliance Statistics and Data Center, Mayo Clinic, Rochester, MN.
Lori A EricksonDivision of Medical Oncology, Mayo Clinic, Rochester, MN.
Kandelaria M RumillaDepartment of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN.
Matthew S BlockDivision of Medical Oncology, Mayo Clinic, Rochester, MN.
Michael KeppenSanford USD Medical Center-Sioux Falls, Sioux Falls, SD.
David KingUnity Hospital, Fridley, MN.
Svetomir N MarkovicDivision of Medical Oncology, Mayo Clinic, Rochester, MN.
Robert R McWilliamsDivision of Medical Oncology, Mayo Clinic, Rochester, MN.
Mayo Clinic in Arizona · USMayo Clinic · USRush University Medical Center · USSanford USD Medical Center · USUnity Hospital · US
Funding
Member Site CoreU10CA180821 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI Evanthia Galanis · 2014 to 2026
$177.3M
Women's Cancer ProgramP30CA015083 · NCI · MAYO CLINIC ROCHESTER · PI AKHILESH PANDEY · 1985 to 2026
$151.3M
Statistics CoreU10CA180882 · NCI · MAYO CLINIC ROCHESTER · PI Sumithra Jay Mandrekar · 2014 to 2026
$115.0M
TRANSLATIONAL RESEARCHU10CA025224 · NCI · MAYO CLINIC ROCHESTER · PI BUCKNER, JAN C · 1985 to 2013
$85.0M
Metro-Minnesota Community Oncology Research Consortium (MMCORC)UG1CA189863 · NCI · PARK NICOLLET INSTITUTE · PI JOLEEN M HUBBARD, Yan Ji · 2014 to 2026
$43.2M
THE ALLIANCE NCTN BIOREPOSITORY AND BIOSPECIMEN RESOURCEU24CA196171 · NCI · WASHINGTON UNIVERSITY · PI Mine Cicek, Wendy Frankel · 2015 to 2026
$35.0M
Sanford Community Cancer Program of the North Central Plains (NCORP)UG1CA189825 · NCI · SANFORD RESEARCH/USD · PI Daniel Almquist, SAMUEL J. MILANOVICH · 2014 to 2026
$13.6M
Naional Cancer Institute, Naitonal Clinical Trials Network U10 Lead Academic SiteU10CA180790 · NCI · MAYO CLINIC ROCHESTER · PI ALBERTS, STEVEN R, BOUGHEY, JUDY CAROLINE · 2014 to 2018
objectiveTo evaluate the prognostic significance of detectable circulating cell-free DNA (cfDNA) PATIENTS AND
methods
resultsIn total, 63 of 149 (42.3%) patients had
conclusionIn advanced melanoma, detectable cfDNA
Indexed as
cfDNA, cell-free DNAddPCR, digital droplet polymerase chain reactionFFPE, formalin-fixed paraffin-embeddedHR, hazard ratioLDH, lactate dehydrogenaseMAPK, mitogen-activated protein kinaseNA, not availableNCCTG, North Central Cancer Treatment GroupNPV, negative predictive valueOS, overall survivalPFS, progression-free survivalPPV, positive predictive value
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.